The FDA has approved the use of SEROQUEL in children and adolescents for the following indications:
- Children and Adolescents (10-17 years) for Bipolar Mania, monotherapy with dose range 400-600mg/day
- Adolescents (13-17 years) for Schizophrenia with dose range 400-800mg/day
: The safety and effectiveness of SEROQUEL XR has not been evaluated in pediatric patients.
Please click to review the revised SEROQUEL label
For the highest-quality video, please view videos in the latest browser available.
If you have any questions or issues, please contact